Because vascular endothelial growth factor (VEGF, also known as VEGF-A) plays predominant roles in this complex process by promoting proliferation, migration, and survival of endothelial cells (ECs), drugs inhibiting VEGF signaling have been globally administered to suppress deregulated angiogenesis in a variety of eye diseases, including age-related macular degeneration [2], [3] and retinopathy of prematurity [4]. This evidence concerns the gene VEGFA and age-related macular degeneration.